Satellos Bioscience (MSLE) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Satellos Bioscience (MSLE) over the past year, gaining 1.5% versus a loss of 5.3%. Over five years, MSLE leads with a -58.5% price change compared with -98.2% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($133.6 million vs $120.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MSLE | ZNTL |
|---|---|---|
| Share price | $5.68 | $1.36 |
| Market cap | $120.51M | $133.64M |
| 1-day change | -2.07% | 0.00% |
| YTD return | -3.40% | +0.74% |
| 1-year return | -5.33% | +1.49% |
| 5-year return | -58.48% | -98.21% |
| EPS (TTM) | $-2.12 | $-1.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-24.87M | $-137.06M |
| 52-week high | $13.40 | $6.95 |
| 52-week low | $5.44 | $1.30 |
| Distance from 52-week high | -57.60% | -80.43% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +325.53% | +447.06% |
| Average volume | 51.19K | 1.26M |
| Shares outstanding | 21.22M | 98.27M |
| Employees | 18 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
MSLE vs ZNTL FAQ
Which is bigger, Satellos Bioscience or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $133.64M compared with $120.51M for Satellos Bioscience (MSLE).
Which stock has performed better over the past year, MSLE or ZNTL?
ZNTL returned +1.49% over the past 12 months, compared with -5.33% for MSLE (price return, excluding dividends). Past performance does not predict future results.
Are Satellos Bioscience and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.